Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
5 p, 637.4 KB Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty / Lordick, Florian (Leipzig University Medical Center) ; Obermannova, Radka (Masaryk University) ; Vola, Doris (European Society for Medical Oncology) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Mcgregor, Keith (European Society for Medical Oncology) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ciardiello, Fortunato (Second University of Naples) ; Cervantes, Andrés (Universitat de València)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)  
2.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D. C. (The West Clinic, Memphis, USA) ; Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K. (Aichi Cancer Center Hospital) ; Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A. (Mayo Clinic, Phoenix, USA) ; O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ; Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
3.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Bodoky, G. (St László Hospital (Hongria)) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ; Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K. (Aichi Cancer Center Hospital) ; Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
4.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Van Cutsem, E. (University Hospitals Leuven (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. L. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  

See also: similar author names
4 Obermannova, R.
1 Obermannova, Radka
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.